MGTA

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MGTA, STSA, ROCC, CVT

Retrieved on: 
Wednesday, May 17, 2023
MGTA, CVR, Empire, Sale, Primary energy, ROCC, Monteverde, Therapy, CVT, Blackstone Inc., Security (finance), Fenthion

Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company.

Key Points: 
  • Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company.
  • Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA ), relating to its proposed sale to Shin Nippon Biomedical Laboratories, Ltd.
  • Under the terms of the agreement, ROCC shareholders are expected to receive 7.49 shares of Baytex and $13.31 in cash per share they own.
  • Cvent Holding Corp. (NASDAQ: CVT ), relating to its sale to equity funds managed by Blackstone Inc. Click here for more information: https://www.monteverdelaw.com/case/cvent-holding-corp .

Lifshitz Law PLLC Announces Investigations of RUTH, MGTA, MDWT, and ISEE

Retrieved on: 
Sunday, May 14, 2023
Telephone, Sale, ISEE, MGTA, Advertising, Hewlett, Life insurance, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of MGTA and Dianthus Therapeutics, Inc.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of MGTA and Dianthus Therapeutics, Inc.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of MDWT to Antarctica Capital for $27.00 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ISEE to Astellas Pharma Inc. for $40.00 per share in cash.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

Retrieved on: 
Friday, December 4, 2020
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Health in Africa, Hematopathology, Sickle cell disease, Plerixafor, Bluebird bio, MGTA, bluebird bio, Inc., Magenta Therapeutics

Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).
  • Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models.
  • The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.
  • We look forward to collaborating with bluebird bio to evaluate MGTA-145 as the preferred mobilization option for people with sickle cell disease.

Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results

Retrieved on: 
Thursday, November 5, 2020
Other Health, Research, General Health, Pharmaceutical, Genetics, Clinical trials, Science, Biotechnology, Stem cells, AIDS, Other Science, Health, MGTA

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the third quarter ended September 30, 2020.

Key Points: 
  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the third quarter ended September 30, 2020.
  • Magenta showed steady progress throughout the third quarter, bringing aboard new scientific leadership in Lisa Olson to broaden our technical expertise across research and discovery.
  • By the end of 2020, Magenta plans to initiate multiple Phase 2 clinical trials of MGTA-145, the Companys first-line stem cell mobilization agent.
  • The MGTA-145 Phase 1 trial in healthy volunteers was completed earlier this year and met all primary and secondary endpoints.

Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Health, Stem cells, Clinical trials, General Health, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, MGTA, American Society of Hematology

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held December 5-8, 2020.

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held December 5-8, 2020.
  • All primary and secondary endpoints were met in the MGTA-145 Phase 1 trial in healthy volunteers completed earlier this year.
  • By the end of 2020, Magenta intends to initiate multiple Phase 2 clinical trials of MGTA-145.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

DGAP-News: Heidelberg Pharma Receives Milestone Payment from Partner Magenta

Retrieved on: 
Monday, September 14, 2020
MGTA, Magenta Therapeutics, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 14 September 2020 - Heidelberg Pharma AG (FSE: HPHA) announced today that it has received a milestone payment from its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) associated with the initiation of the GLP toxicology study for the development candidate MGTA-117.

Key Points: 
  • Ladenburg, Germany, 14 September 2020 - Heidelberg Pharma AG (FSE: HPHA) announced today that it has received a milestone payment from its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) associated with the initiation of the GLP toxicology study for the development candidate MGTA-117.
  • Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are delighted that Magenta is advancing the program forward toward clinical trials for MGTA-117.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.